REG - AstraZeneca PLC - Second Quarter & Half Year Results 2014 <Origin Href="QuoteRef">AZN.L</Origin> - Part 3
06/09/2014 22:42
- Part 3: For the preceding part double click ID:nRSe8344Nb
acquisition approximates the gross contractual amounts receivable.
There are no significant amounts which are not expected to be collected.
The results from the additional acquired interests in the diabetes alliance have been consolidated into the Company's
results from 1 February 2014, which have added revenue of $382 million in the period to 30 June 2014. Due to the highly
integrated nature of the diabetes alliance, and the fact that it is not operated through a separate legal entity, the
incremental direct costs associated with the additional acquired interest are not separately identifiable and it is
impracticable therefore to disclose the profit or loss recognised in the period since acquisition.
Fair value*$m
Non-current assets
Intangible assets 5,746
Property, plant and equipment 478
6,224
Current assets 519
Current liabilities (311)
Non-current liabilities (99)
Total net assets acquired 6,333
Goodwill 1,619
Fair value of total consideration 7,952
Less: fair value of contingent consideration (5,249)
Total upfront consideration 2,703
Less: cash and cash equivalents acquired -
Net cash outflow 2,703
* Under the terms of the agreement, working capital balances are subject to true-up post closure. We expect this process to
be completed in the second half of 2014.
As detailed above, future contingent consideration has been recognised initially at fair value and is revalued to fair
value at each balance sheet date. Changes in fair value can arise as a result of a number of factors, including external
news flow and internal re-forecasts, which may affect the likelihood of specific milestones becoming payable or the
expected quantum of future royalty payments. These changes, which are potentially volatile and material, are included
within selling, general and administrative costs. They are excluded from the Group's Core results.
The fair value of contingent consideration is also affected over time by the unwinding effect of discounting. This effect
gives a charge to finance income and expense which reduces over time as the liability reduces. As a direct result of a
material business acquisition, this effect is excluded from the Group's Core results.
In the period between acquisition and 30 June 2014, the effect of discounting increased the contingent consideration
liability by $156 million and revaluations increased fair value by $6 million. Cash payments in the period since
acquisition totaled $449 million.
In addition, inventory acquired at completion has been recorded at fair value, which is higher than manufacturing cost. The
adjustment to increase the inventory to fair value is held in inventory until product is sold, at which time it is released
to profit as a cost of sale. This results in a lower gross margin in the first turn of inventory and, since this arises as
a direct result of a material business acquisition, this effect is excluded from the Group's Core results. The charge to
cost of sales in the period since acquisition was $137 million and represents the majority of the total adjustment to the
fair value of inventory.
5 FINANCIAL INSTRUMENTS
As detailed in our most recent annual financial statements, our principal financial instruments consist of derivative
financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables
including contingent consideration arising on business combinations, and interest-bearing loans and borrowings. As
indicated in Note 1, there have been no changes to the accounting policies, including fair value measurement, for financial
instruments from those disclosed on page 139 of the Company's Annual Report and Form 20-F Information 2013. In addition,
there have been no changes of significance to the categorisation or fair value hierarchy of our financial instruments.
Financial instruments measured at fair value include $1,108 million of other investments, $1,216 million of loans, and $338
million of derivatives as at 30 June 2014. The total fair value of interest-bearing loans and borrowings at 30 June 2014,
which have a carrying value of $10,074 million in the Condensed Consolidated Statement of Financial Position, was $11,195
million. Contingent consideration liabilities arising on the Company's acquisitions of business combinations have been
classified under Level 3 in the fair value hierarchy and movements in fair value are shown below:
2014
$m
At 1 January 514
Acquisitions 5,249
Settlements (449)
Revaluations 6
Discounting 174
Foreign exchange 6
At 30 June 5,500
For all other financial instruments which are carried at amortised cost, amortised cost approximates to fair value.
6 legal proceedings and contingent liabilities
AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and
investigations relating to product liability, commercial disputes, infringement of intellectual property rights, the
validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the
more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual
Report and Form 20-F Information 2013 (the 2013 Disclosures). Unless noted otherwise below or in the 2013 Disclosures, no
provisions have been established in respect of the claims discussed below.
As discussed in the 2013 Disclosures, for the majority of claims in which AstraZeneca is involved it is not possible to
make a reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the
proceedings. In these cases, AstraZeneca discloses information with respect only to the nature and facts of the cases but
no provision is made.
In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are
not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, we record the
loss absorbed or make a provision for our best estimate of the expected loss.
The position could change over time and the estimates that we have made and upon which we have relied in calculating these
provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of
any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors
causing this uncertainty are described more fully in the 2013 Disclosures and herein.
AstraZeneca has full confidence in, and will vigorously defend and enforce, its intellectual property.
Matters disclosed in respect of the first quarter of 2014 and April 2014
Patent litigation
Crestor (rosuvastatin calcium)
Patent proceedings outside the US
On 1 April 2014, Shionogi & Co. Ltd, the licensor of the Crestor patent, received confirmation of a request for trial for
patent invalidation in the Japanese Patent Office. The request was initiated by Teva Pharma Japan Inc. and relates to the
substance patent.
On 17 April 2014, AstraZeneca received a writ of summons from Resolution Chemicals Ltd. (Resolution) challenging the
validity of Supplementary Protection Certificate 300125 for Crestor in the Netherlands. Resolution also seeks a declaration
of non-infringement of its rosuvastatin zinc product that it intends to market in the Netherlands.
Epanova
Patent proceedings in the US
In March 2014, AstraZeneca received a complaint from Amarin Pharmaceuticals Ireland Ltd. alleging that AstraZeneca's
proposed Epanova product (for the treatment of patients with severe hypertriglyceridaemia) infringes US Patent No.
8,663,662. On 18 September 2013, AstraZeneca announced that the FDA had accepted for review a NDA Application for Epanova
and the Prescription Drug User Fee Act goal date for the FDA is 5 May 2014.
Pulmicort Respules (budesonide inhalation suspension)
Patent proceedings in the US
As previously disclosed, in December 2013, the US District Court for the District of New Jersey granted AstraZeneca's
motion and temporarily enjoined the generic defendants from entering the market until resolution of AstraZeneca's motion
for a preliminary injunction. On 1 April 2014, the Court entered an order scheduling oral argument on AstraZeneca's motion
for a preliminary injunction for 9 May 2014.
Faslodex (fulvestrant)
Patent proceedings in the US
In April 2014, Sandoz Inc. sent notice that it had submitted an Abbreviated New Drug Application (ANDA) for fulvestrant
injection, 250mg/5ml containing a Paragraph IV Certification alleging that patents listed in the FDA Orange Book with
reference to Faslodex are invalid, unenforceable and/or will not be infringed by the Sandoz product as described in its
ANDA. The challenged patents are US Patent Nos. 6,774,122; 7,456,160; 8,329,680 and 8,466,139.
Patent proceedings outside the US
As previously disclosed, in Europe, in 2008, the Opposition Division of the European Patent Office (EPO) maintained a
Faslodex formulation patent, EP 1250138, following an opposition against the grant of this patent by Gedeon Richter Plc,
which appealed this decision. The Board of Appeal of the EPO called the parties to oral proceedings in March 2014 and
decided to remit the case back to the Opposition Division for further consideration.
Nexium (esomeprazole magnesium)
Patent proceedings outside the US
As previously disclosed, in the UK, in 2010, AstraZeneca initiated patent infringement proceedings against Consilient
Health Limited and Krka, d.d. Novo Mesto (Consilient/Krka). During previous proceedings, Consilient/Krka agreed not to
launch their esomeprazole magnesium product. This injunction was discharged in July 2011. In March 2014, in damages
proceedings initiated by Consilient/Krka, the High Court awarded Consilient/Krka £27.4 million in damages. AstraZeneca is
considering its legal options including seeking leave to appeal. A provision has been taken.
Onglyza (saxagliptin)
Patent proceedings in the US
In April 2014, multiple generic companies sent notices that they had submitted Abbreviated New Drug Applications (ANDAs)
for saxagliptin hydrochloride 2.5mg and 5mg tablets containing Paragraph IV Certifications alleging that US Patent No.
7,951,400 and/or RE44,186, listed in the FDA Orange Book with reference to Onglyza, are invalid, unenforceable and/or will
not be infringed by the products as described in the ANDAs.
Seroquel XR (quetiapine fumarate)
Patent proceedings outside the US
As previously disclosed, in Germany, Ratiopharm GmbH, CT Arzneimittel GmbH and AbZ Pharma GmbH are seeking damages relating
to the preliminary injunction issued in April 2012 that prevented generic Seroquel XR sales by those entities. The
injunction was subsequently lifted following the November 2012 Federal Patent Court (the Federal Court) decision that held
that the Seroquel XR patent was invalid. AstraZeneca has appealed the Federal Court's decision.
In Romania, in March 2014, AstraZeneca settled patent litigation with Teva Pharmaceutical Industries Ltd. and Teva
Pharmaceuticals S.R.L.
Product liability litigation
Byetta/Bydureon (exenatide)
As previously disclosed, Amylin Pharmaceuticals, LLC, a wholly owned subsidiary of AstraZeneca, and/or AstraZeneca are
among multiple defendants in various lawsuits filed in federal and state courts in the US involving approximately 409
plaintiffs claiming physical injury from treatment with Byetta and/or Bydureon. The lawsuits allege multiple types of
injuries including pancreatitis, pancreatic cancer and thyroid cancer. A Multi-District Litigation has been established in
the US District Court for the Southern District of California in regard to the alleged pancreatic cancer cases in federal
courts. Further, a coordinated proceeding has been established in Los Angeles, California in regard to the various lawsuits
in California state courts. AstraZeneca and certain defendants recently reached an agreement to settle 84 cases pending in
the California state court proceeding, including a matter that was scheduled for trial in February 2014.
Nexium (esomeprazole magnesium)
As previously disclosed, in December 2013, 522 already dismissed plaintiffs collectively moved the federal Multi-District
Litigation court (the MDL Court) to have their claims reinstated, and AstraZeneca opposed that motion. In March 2014, more
than 440 of the 522 plaintiffs seeking reinstatement failed to satisfy certain court-imposed conditions for reinstatement,
and their claims are in the process of being dismissed with prejudice. AstraZeneca has withdrawn its opposition to more
than 50 of the 522 plaintiffs' requests for reinstatement after they satisfied certain court-imposed conditions, and those
plaintiffs' claims will be reinstated. The remaining of the 522 plaintiffs' requests for reinstatement remain outstanding
and in dispute. In addition, in February 2014, the MDL Court dismissed the claims of an additional 62 plaintiffs.
Commercial litigation
Average Wholesale Price (AWP) Litigation
As previously disclosed, AstraZeneca and other pharmaceutical manufacturers were named as defendants in litigation
involving allegations that, by causing the publication of allegedly inflated wholesale list prices, defendants caused
entities to overpay for prescription drugs. In March 2014, AstraZeneca reached a settlement with the State of Utah and in
April 2014, AstraZeneca reached a settlement in principle with the State of Wisconsin. With these settlements, AstraZeneca
has brought the AWP litigation to a conclusion.
Crestor qui tam litigation
As previously disclosed, the US Attorney's Offices and all US states, except for the State of Texas, have declined to
intervene in the civil component of a previously disclosed investigation regarding Crestor. Partly as a result thereof,
AstraZeneca was served with two additional lawsuits filed in the US District Court for the District of Delaware under the
qui tam (whistleblower) provisions of the federal False Claims Act and related state statutes, alleging that AstraZeneca
directed certain employees to promote Crestor off-label and provided unlawful remuneration to physicians in connection with
the promotion of Crestor. AstraZeneca intends to vigorously defend these matters.
Nexium settlement anti-trust litigation
As previously disclosed, AstraZeneca is one of several defendants in a Multi-District Litigation proposed class action and
individual lawsuits alleging that AstraZeneca's settlements of certain patent litigation in the US relating to Nexium
violated US anti-trust law and various state laws. On 12 February 2014, the US District Court for the District of
Massachusetts (the Court) issued an order granting three motions for summary judgment in full, granting two in part,
denying one as premature, and denying five.
In particular, the Court held that AstraZeneca's settlement agreements with Teva and Dr. Reddy's Laboratories did not
include "large, unjustified reverse payments" that would raise anti-trust concerns. The Court granted the motion as to the
Ranbaxy agreement because plaintiffs could not establish that the agreement delayed generic entry beyond any delay caused
by Ranbaxy's manufacturing and approval issues. The Court denied the motion seeking judgment on the allegation of a
conspiracy among all defendants.
The Court initially indefinitely postponed the trial and administratively closed the case pending the issuance of written
decisions. On 17 April 2014, the Court granted the plaintiffs' motion for reconsideration of the motion directed to the
Teva agreement and decided that there was sufficient evidence to proceed to trial on the question of whether the Teva
settlement raised anti-trust concerns. The Court scheduled an October 2014 trial on the plaintiffs' claims that remain in
the case. The Court's decisions are subject to further motions, including additional motions for reconsideration, and
appeal.
Separately, AstraZeneca was notified that indirect purchaser plaintiffs who opted out of the Massachusetts class action
intend to file complaints in the Pennsylvania Court of Common Pleas.
Government investigations
Medco New Jersey subpoena
In April 2014, AstraZeneca was served with a subpoena from the New Jersey Attorney General's Office seeking certain
documents relating to the price of Nexium and/or its business relationships with Medco Health Solutions, Inc. and Express
Scripts Holding Company.
Matters disclosed in respect of the second quarter of 2014 and July 2014
Patent litigation
Crestor (rosuvastatin calcium)
Patent proceedings outside the US
As previously disclosed, in March 2014, AstraZeneca received a letter from Resolution Chemicals Ltd. (Resolution)
indicating that it had sought marketing authorisation for a rosuvastatin zinc product in the Netherlands. On 17 April 2014,
AstraZeneca received a writ of summons from Resolution regarding partial invalidity and non-infringement of the
supplementary protection certificate related to the Crestor substance patent. AstraZeneca will respond.
Faslodex (fulvestrant)
Patent proceedings in the US
As previously disclosed, in April 2014, Sandoz Inc. (Sandoz) sent notice that it had submitted an Abbreviated New Drug
Application (ANDA) for fulvestrant injection, 250mg/5ml containing a Paragraph IV Certification alleging that four
AstraZeneca patents listed in the FDA Orange Book with reference to Faslodex are invalid, unenforceable and/or will not be
infringed by the product as described in its ANDA. In June 2014, AstraZeneca filed a patent infringement lawsuit against
Sandoz and Sandoz International GmbH in the US District Court in New Jersey relating to all four listed patents.
Nexium (esomeprazole magnesium)
Patent proceedings outside the US
As previously disclosed, in Canada, patent infringement proceedings against Apotex Inc. (Apotex) continue. A trial was
held from September to November 2013. On 2 July 2014, the Federal Court found Canadian patent no. 2,139,653 invalid as a
result of the requirements of the uniquely Canadian promise doctrine. AstraZeneca is considering its options. Apotex
launched its esomeprazole product in 2011.
As previously disclosed, in Canada, in October 2012, the Federal Court prohibited Pharmascience Inc. (PMS) from receiving a
marketing authorisation for its esomeprazole magnesium product until May 2018. PMS appealed. On 22 May 2014, the Federal
Court of Appeal reversed the decision. PMS has now received its marketing authorisation.
Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin)
Patent proceedings in the US
Beginning in April 2014, a number of generics companies sent notices that they had submitted Abbreviated New Drug
Applications (ANDAs) for saxagliptin hydrochloride 2.5mg and 5mg tablets containing a Paragraph IV Certification alleging
that US Patent Nos. 7,951,400, and RE44,186, listed in the FDA Orange Book with reference to Onglyza, are invalid,
unenforceable and/or will not be infringed by the products as described in the ANDAs. Certain of the generics companies
sent notices that they had also submitted ANDAs for saxagliptin hydrochloride and metformin 2.5mg/1000mg, 5mg/1000mg, and
5mg/500mg tablets containing a Paragraph IV Certification alleging that US Patent Nos. 8,628,799, 7,951,400, and/or
RE44,186, listed in the FDA Orange Book with reference to Kombiglyze XR, are invalid, unenforceable and/or will not be
infringed by the products as described in the ANDAs. AstraZeneca has filed lawsuits in the US Federal Court in Delaware
against all of the above-referenced patent challengers. The lawsuits are in their early stages and no schedule has yet been
established.
Pulmicort Respules (budesonide inhalation suspension)
Patent proceedings in the US
As previously disclosed, in December 2013, the US District Court for the District of New Jersey temporarily enjoined the
generic defendants from entering the market until resolution of AstraZeneca's motion for a preliminary injunction. In June
2014, the Court entered an order reserving decision on the preliminary injunction motion and scheduled a hearing on the
motion, as well as a trial on the merits, to commence on 6 October 2014.
Seroquel XR (quetiapine fumarate)
Patent proceedings outside the US
In the Netherlands, in June 2014, the Dutch Court of Appeal in The Hague reversed the March 2012 opinion of the Commercial
Court and found the Seroquel XR formulation patent invalid.
In France, by summons served in July 2014, Accord Healthcare France SAS and Accord Healthcare Limited initiated an action
seeking to revoke the Seroquel XR formulation patent.
Product liability litigation
Crestor (rosuvastatin calcium)
As previously disclosed, AstraZeneca is defending a number of lawsuits alleging injury caused by the use of Crestor. As of
July, there are 39 lawsuits involving a total of 1,226 plaintiffs. The lawsuits allege multiple types of injuries including
diabetes mellitus, various cardiac injuries, rhabdomyolysis, and liver and kidney injuries. The majority of these lawsuits
were aggregated in one coordinated proceeding in Los Angeles, California.
Nexium (esomeprazole magnesium)
In the second quarter of 2014, the federal Multi-District Litigation Court dismissed the claims of approximately 145
additional plaintiffs, and the parties have stipulated to the dismissal of more than 160 plaintiffs whose claims were
pending in the California Superior Court of Los Angeles County. Of the more than 1,910 plaintiffs who have filed claims
alleging Nexium caused bone-related injuries, currently fewer than 315 plaintiffs' claims remain active.
Commercial litigation
Nexium settlement anti-trust litigation
As previously disclosed, AstraZeneca is one of several defendants in a Multi-District Litigation class action and
individual lawsuits alleging that AstraZeneca's settlements of certain patent litigation in the US relating to Nexium
violated US anti-trust law and various state laws. On 31 July 2014, the US Court of Appeals will hear oral argument on
AstraZeneca's appeal of the District Court's procedural decision to certify a class action of end payers. The District
Court has scheduled trial to begin on 6 October 2014 on the claims that remain in the case.
Separately, indirect purchaser plaintiffs who opted out of the Massachusetts class action filed complaints in the
Pennsylvania Court of Common Pleas. On 8 July 2014, AstraZeneca filed papers seeking to move those complaints to the US
Federal Court.
Government investigations
Seroquel IR and Seroquel XR (quetiapine fumarate)
As previously disclosed, in January 2014, the US Department of Justice advised AstraZeneca that it declined to intervene in
qui tam (whistleblower) lawsuits relating to marketing activities involving Seroquel IR and XR. On 29 April 2014, the qui
tam plaintiff served AstraZeneca with the underlying civil complaint, which is pending in the US District Court in
Delaware.
7 FIRST HALF PRODUCT REVENUE ANALYSIS
World US Europe Established ROW Emerging Markets
H1 2014$m CER% H1 2014$m CER H1 2014$m CER% H1 2014$m CER% H1 2014$m CER%
%
Cardiovascular and Metabolic disease:
Crestor 2,782 - 1,476 4 611 (6) 338 (14) 357 10
Seloken/Toprol-XL 386 (1) 53 (39) 63 (8) 10 (15) 260 15
Onglyza 400 108 250 80 69 144 27 211 54 217
Atacand 261 (21) 20 (61) 96 (21) 22 (43) 123 4
Brilinta/Brilique 216 84 63 103 110 54 14 167 29 173
Byetta 166 72 105 35 40 192 12 250 9 n/m
Bydureon 192 224 164 204 24 n/m 3 n/m 1 n/m
Plendil 122 (5) - - 10 - 4 (33) 108 (4)
Tenormin 81 (16) 4 (43) 25 (4) 29 (18) 23 (17)
Others 227 29 59 157 92 13 18 50 58 (2)
Total Cardiovascular and Metabolic disease 4,833 10 2,194 16 1,140 6 477 (8) 1,022 14
Oncology:
Zoladex 457 (6) 11 (8) 117 (15) 156 (8) 173 5
Iressa 316 - - - 84 (10) 89 - 143 7
Faslodex 351 7 161 5 123 8 28 7 39 16
Arimidex 156 (8) 9 n/m 41 (19) 55 (24) 51 6
Casodex 166 (7) 3 200 22 (22) 88 (14) 53 15
Others 66 (1) 13 - 16 23 19 (25) 18 20
Total Oncology 1,512 (2) 197 11 403 (8) 435 (10) 477 8
Respiratory, Inflammation and Autoimmunity:
Symbicort 1,856 11 721 25 757 (5) 211 27 167 17
Pulmicort 472 7 104 (12) 89 (9) 47 (6) 232 31
Others 155 (4) 17 (39) 59 (8) 11 - 68 15
Total Respiratory, Inflammation and Autoimmunity 2,483 9 842 17 905 (5) 269 18 467 23
Infection, Neuroscience and Gastrointestinal:
Nexium 1,901 (1) 939 (13) 194 3 335 28 433 9
Synagis 375 (10) 259 (17) 116 13 - - - -
Seroquel XR 596 (10) 347 (2) 181 (16) 20 (52) 48 -
Seroquel IR 155 (30) 26 n/m 47 (20) 21 (73) 61 (23)
Local Anaesthetics 249 1 - - 106 (3) 80 (2) 63 11
Losec/Prilosec 215 (11) 14 (13) 67 (2) 54 (30) 80 3
Merrem 130 (9) 6 50 16 (44) 2 (33) 106 (2)
FluMist/Fluenz 12 71 10 43 - - 2 n/m - -
Others 409 - 117 (15) 102 (2) 66 7 124 16
Total Infection, Neuroscience and Gastrointestinal 4,042 (5) 1,718 (10) 829 (5) 580 (3) 915 4
Total 12,870 3 4,951 5 3,277 (2) 1,761 (4) 2,881 11
8 SECOND QUARTER PRODUCT REVENUE ANALYSIS
World US Europe Established ROW Emerging Markets
Q2 2014$m CER% Q2 2014$m CER Q2 2014$m CER% Q2 2014$m CER% Q2 2014$m CER%
%
Cardiovascular and Metabolic disease:
Crestor 1,450 (2) 771 1 310 (4) 182 (18) 187 8
Seloken/Toprol-XL 193 10 29 (6) 32 (12) 5 (14) 127 23
Onglyza 238 131 144 92 43 193 16 n/m 35 270
Atacand 139 (16) 9 (63) 47 (21) 11 (38) 72 12
Brilinta/Brilique 117 77 35 119 58 42 8 125 16 143
Byetta 88 61 53 47 23 62 7 125 5 n/m
Bydureon 112 247 95 252 15 180 2 n/m - -
Plendil 53 (14) - - 5 - 2 (50) 46 (13)
Tenormin 42 (21) 2 (60) 13 - 16 (15) 11 (31)
Others 133 45 40 233 48 29 13 86 32 (8)
Total Cardiovascular and Metabolic disease 2,565 12 1,178 19 594 8 262 (9) 531 15
Oncology:
Zoladex 236 (8) 5 (17) 59 (15) 81 (11) 91 -
Iressa 147 (5) - - 41 (14) 39 (20) 67 13
Faslodex 179 3 85 5 60 4 13 (7) 21 5
Arimidex 78 (5) 4 180 20 (17) 28 (28) 26 8
Casodex 83 (11) 2 100 11 (23) 45 (17) 25 4
Others 35 - 7 17 8 14 10 (21) 10 13
Total Oncology 758 (5) 103 16 199 (10) 216 (17) 240 6
Respiratory, Inflammation and Autoimmunity:
Symbicort 928 9 377 30 371 (7) 96 2 84 11
Pulmicort 209 - 52 (7) 43 - 22 (21) 92 10
Others 75 (7) 5 (64) 31 (6) 5 - 34 16
Total Respiratory, Inflammation and Autoimmunity 1,212 6 434 21 445 (6) 123 (3) 210 12
Infection, Neuroscience and Gastrointestinal:
Nexium 971 (4) 455 (18) 100 7 184 24 232 10
Synagis 47 327 3 (250) 44 246 - - - -
Seroquel XR 304 (11) 181 (2) 88 (22) 11 (48) 24 9
Seroquel IR 89 (8) 19 n/m 23 (19) 14 (64) 33 -
Local Anaesthetics 127 (1) - - 53 (4) 40 (11) 34 19
Losec/Prilosec 105 (12) 6 (33) 33 - 28 (31) 38 9
Merrem 65 (16) 2 (67) 7 (50) 1 - 55 (5)
FluMist/Fluenz 5 150 5 150 - - - - - -
Others 206 2 52 (19) 54 15 37 3 63 15
Total Infection, Neuroscience and Gastrointestinal 1,919 (3) 723 (11) 402 2 315 (5) 479 8
Total 6,454 4 2,438 8 1,640 - 916 (9) 1,460 11
Shareholder Information
ANNOUNCEMENTS AND MEETINGS
______________________________________________________________________________________________________________________________________________________________________________________________________________________________
Announcement of third quarter and nine months 2014 results 6 November 2014
Announcement of fourth quarter and full year 2014 results 5 February 2015
DIVIDENDS
______________________________________________________________________________________________________________________________________________________________________________________________________________________________
The record date for the first interim dividend payable on 15 September 2014 is 15 August 2014. Shares will trade
ex-dividend from 13 August 2014.
Future dividends will normally be paid as follows:
First interim Announced with second quarter and half year results and paid in September
Second interim Announced with fourth quarter and full year results and paid in March
TRADEMARKS
______________________________________________________________________________________________________________________________________________________________________________________________________________________________
Trademarks of the AstraZeneca group of companies and of companies other than AstraZeneca appear throughout this document in
italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of
companies. Trademarks of companies other than AstraZeneca that appear in this document include Epanova, a trademark of
Chrysalis Pharma AG and Eklira, a trademark of Almirall, S.A.
ADDRESSES FOR CORRESPONDENCE
______________________________________________________________________________________________________________________________________________________________________________________________________________________________
Registrar andTransfer OfficeEquiniti LimitedAspect HouseSpencer RoadLancingWest SussexBN99 6DAUK US DepositaryJP Morgan Chase & CoPO Box 64504St PaulMN 55164-0504US Registered Office2 Kingdom StreetLondonW2 6BDUK Swedish Central Securities DepositoryEuroclear Sweden ABPO Box 191SE-101 23 StockholmSweden
Tel (freephone in UK): Tel (toll free in US): 888 697 8018Tel (outside US): +1 (651) 453 2128 Tel: +44 (0)20 7604 8000 Tel: +46 (0)8 402 9000
0800 389 1580Tel (outside UK):
+44 (0)121 415 7033
CONTACT INFORMATION
______________________________________________________________________________________________________________________________________________________________________________________________________________________________
Media Enquiries: Esra Erkal-Paler (London) +44 20 7604 8030
Vanessa Rhodes (London) +44 20 7604 8037
Ayesha Bharmal (London) +44 20 7604 8034
Jacob Lund (Södertälje) +46 8 553 260 20
Analyst/Investor Enquiries: Karl Hård (London) +44 20 7604 8123
Anthony Brown (London) +44 20 7604 8067
Jens Lindberg (London) +44 20 7604 8414
Eugenia Litz (London) +44 20 7604 8233
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
______________________________________________________________________________________________________________________________________________________________________________________________________________________________
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act
1995, we are providing the following cautionary statement: The interim financial statements contain certain forward-looking
statements with respect to the operations, performance and financial condition of the Group. Although we believe our
expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and
uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from
those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of
the interim financial statements and AstraZeneca undertakes no obligation to update these forward-looking statements. We
identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar
expressions in such statements. Important factors that could cause actual results to differ materially from those contained
in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration
of patents, marketing exclusivity or trademarks, or the risk of failure to obtain patent protection; the risk of
substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate
fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic
alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation
risks; the risk of substantial product liability claims; the impact of any delays in the manufacturing, distribution and
sale of any of our products; the impact of any failure by third parties to supply materials or services; the risk of
failure to manage a crisis; the risk of failure of information technology and cybercrime; the risk of delay to new product
launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe
ongoing regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental
liabilities; the risks associated with conducting business in emerging markets; the risk of reputational damage; the risk
of product counterfeiting; the risk of failure to successfully implement planned cost reduction measures through
productivity initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could
have an adverse effect on future commercial prospects; the impact of failing to attract and retain key personnel and to
successfully engage with our employees; and the impact of increasing implementation and enforcement of more stringent
anti-bribery and anti-corruption legislation.
This information is provided by RNS
The company news service from the London Stock ExchangeRecent news on AstraZeneca
See all newsRCS - LHH - LHH, EZRA's AI Leadership Transformation Program
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpoint in Bax24 Ph3 trial
AnnouncementREG - AstraZeneca PLC - Datroway improved OS and PFS in TROPION-Breast02
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Enhertu improved IDFS in early BC in DB-05
Announcement